- Home
- RRGB vs IMAB Comparison
RRGB vs IMAB Comparison
Compare RRGB & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- IMAB
- Stock Information
- Founded
- RRGB 1969
- IMAB 2014
- Country
- RRGB United States
- IMAB United States
- Employees
- RRGB N/A
- IMAB N/A
- Industry
- RRGB Restaurants
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- IMAB Health Care
- Exchange
- RRGB Nasdaq
- IMAB Nasdaq
- Market Cap
- RRGB 88.7M
- IMAB 200.9M
- IPO Year
- RRGB 2002
- IMAB 2020
- Fundamental
- Price
- RRGB $5.94
- IMAB $2.45
- Analyst Decision
- RRGB Strong Buy
- IMAB Strong Buy
- Analyst Count
- RRGB 4
- IMAB 2
- Target Price
- RRGB $11.88
- IMAB $6.00
- AVG Volume (30 Days)
- RRGB 836.0K
- IMAB 1.2M
- Earning Date
- RRGB 08-21-2025
- IMAB 05-15-2025
- Dividend Yield
- RRGB N/A
- IMAB N/A
- EPS Growth
- RRGB N/A
- IMAB N/A
- EPS
- RRGB N/A
- IMAB N/A
- Revenue
- RRGB $1,252,370,000.00
- IMAB N/A
- Revenue This Year
- RRGB $0.04
- IMAB N/A
- Revenue Next Year
- RRGB N/A
- IMAB N/A
- P/E Ratio
- RRGB N/A
- IMAB N/A
- Revenue Growth
- RRGB N/A
- IMAB N/A
- 52 Week Low
- RRGB $2.50
- IMAB $0.60
- 52 Week High
- RRGB $7.66
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- RRGB 59.37
- IMAB 50.05
- Support Level
- RRGB $4.69
- IMAB $2.35
- Resistance Level
- RRGB $5.59
- IMAB $2.59
- Average True Range (ATR)
- RRGB 0.48
- IMAB 0.35
- MACD
- RRGB -0.09
- IMAB -0.06
- Stochastic Oscillator
- RRGB 37.29
- IMAB 1.86
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).